Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
CONTEXT: Inhaled long-acting beta(2)-agonists improve asthma control when added to inhaled corticosteroid (ICS) therapy. OBJECTIVE: To determine whether ICS therapy can be reduced or eliminated in patients with persistent asthma after adding a long-acting beta(2)-agonist to their treatment regimen. DESIGN AND SETTING: A 24-week randomized, controlled, blinded, double-dummy, parallel-group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from February 1997 through January 1999. PARTICIPANTS: One hundred seventy-five patients aged 12 through 65 years with persistent asthma that was suboptimally controlled during a 6-week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day). INTERVENTION: Patients continued triamcinolone therapy and were randomly assigned to receive add-on therapy with either placebo (placebo-minus group, n = 21) or salmeterol xinafoate, 42 microg twice per day (n = 154) for 2 weeks. The entire placebo-minus group was assigned and half of the salmeterol group (salmeterol-minus group) was randomly assigned to reduce by 50% (for 8 weeks) then eliminate (for 8 weeks) triamcinolone treatment. The other half of the salmeterol group (salmeterol-plus group) was randomly assigned to continue both salmeterol and triamcinolone for the remaining 16 weeks (active control group). MAIN OUTCOME MEASURE: Time to asthma treatment failure in patients receiving salmeterol. RESULTS: Treatment failure occurred in 8.3% (95% confidence interval [CI], 2%-15%) of the salmeterol-minus group 8 weeks after triamcinolone treatment was reduced compared with 2.8% (95% CI, 0%-7%) of the salmeterol-plus group during the same period. Treatment failure occurred in 46.3% (95% CI, 34%-59%) of the salmeterol-minus group 8 weeks after triamcinolone therapy was eliminated compared with 13.7% (95% CI, 5%-22%) of the salmeterol-plus group. The relative risk (95% CI) of treatment failure at the end of the triamcinolone elimination phase in the salmeterol-minus group was 4.3 (2.0-9.2) compared with the salmeterol-plus group (P<.001). CONCLUSIONS: Our results indicate that in patients with persistent asthma suboptimally controlled by triamcinolone therapy alone but whose asthma symptoms improve after addition of salmeterol, a substantial reduction (50%) in triamcinolone dose can occur without a significant loss of asthma control. However, total elimination of triamcinolone therapy results in a significant deterioration in asthma control and, therefore, cannot be recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Juniper, E. F., Guyatt, G. H., Epstein, R. S., Ferrie, P. J., Jaeschke, R., & Hiller, T. K. (1992) · Thorax · doi:10.1136/thx.47.2.76 · Cited by 1,232
Greening, A. P., Ind, P. W., Northfield, M., & Shaw, G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92996-3 · Cited by 972
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
(1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380222 · Cited by 864
Woolcock, A., Lundback, B., Ringdal, N., & Jacques, L. A. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630590 · Cited by 701
Cheung, D., Timmers, M. C., Zwinderman, A. H., Bel, E. H., Dijkman, J. H., & Sterk, P. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271703 · Cited by 455
Eickelberg, O., Roth, M., Lörx, R., Bruce, V., Rüdiger, J., Johnson, M., & Block, L.-H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.1005 · Cited by 378
A Comparison of Salmeterol with Albuterol in the Treatment of Mild-to-Moderate Asthma
Pearlman, D. S., Chervinsky, P., LaForce, C., Seltzer, J. M., Southern, D. L., Kemp, J. P., Dockhorn, R. J., Grossman, J., Liddle, R. F., Yancey, S. W., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272004 · Cited by 362
Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma
Drazen, J. M., Israel, E., Boushey, H. A., Chinchilli, V. M., Fahy, J. V., Fish, J. E., Lazarus, S. C., Lemanske, R. F., Martin, R. J., Peters, S. P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351202 · Cited by 347
Tan, S., Hall, I. P., Dewar, J., Dow, E., & Lipworth, B. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03211-x · Cited by 337
Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma
ANDREW McIVOR, R., PIZZICHINI, E., TURNER, M. O., HUSSACK, P., HARGREAVE, F. E., & SEARS, M. R. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.3.9802069 · Cited by 283
GROWTH SUPPRESSION BY GLUCOCORTICOID THERAPY
Allen, D. B. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70348-0 · Cited by 227
Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network.
Kamada, A. K., Szefler, S. J., Martin, R. J., Boushey, H. A., Chinchilli, V. M., Drazen, J. M., Fish, J. E., Israel, E., Lazarus, S. C., & Lemanske, R. F. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.6.8665030 · Cited by 192
Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.
Juniper, E. F., Johnston, P. R., Borkhoff, C. M., Guyatt, G. H., Boulet, L. P., & Haukioja, A. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.1.7812574 · Cited by 185
Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma
Chervinsky, P., van As, A., Bronsky, E. A., Dockhorn, R., Noonan, M., La Force, C., & Pleskow, W. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(94)90174-0 · Cited by 164
Gardiner, P. V., Ward, C., Booth, H., Allison, A., Hendrick, D. J., & Walters, E. H. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921429 · Cited by 154
Li, X., Ward, C., Thien, F. C. K., BISH, R., Bamford, T. L., Bao, X., Bailey, M., Wilson, J. W., & Walters, E. H. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.5.9811052 · Cited by 148
Wilding, P., Clark, M., Coon, J. T., Lewis, S., Rushton, L., Bennett, J., Oborne, J., Cooper, S., & Tattersfield, A. E. (1997) · BMJ · doi:10.1136/bmj.314.7092.1441 · Cited by 136
The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma
Roberts, J. A., Bradding, P., Britten, K. M., Walls, A. F., Wilson, S., Gratziou, C., Holgate, S. T., & Howarth, P. H. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14b07.x · Cited by 134
An Evaluation of Colchicine as an Alternative to Inhaled Corticosteriods in Moderate Asthma
Fish, J. E., Peters, S. P., Chambers, C. V., McGeady, S. J., Epstein, K., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Drazen, J. M., Fahy, J. V., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.4.9703012 · Cited by 40
Cited by
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Significant variability in response to inhaled corticosteroids for persistent asthma
Szefler, S. J., Martin, R. J., King, T. S., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Craig, T. J., Dolovich, M., Drazen, J. M., Fagan, J. K., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.122635 · Cited by 622
Parsons, J. P., Hallstrand, T. S., Mastronarde, J. G., Kaminsky, D. A., Rundell, K. W., Hull, J. H., Storms, W. W., Weiler, J. M., Cheek, F. M., Wilson, K. C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0437st · Cited by 603
Metadata
- Authors
- Lemanske, Jr.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-05-23
- Volume
- 285
- Issue
- 20
- Pages
- 2594
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2106399406
- Cited by
- 275
- References
- 23
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.